Ocular Therapeutix, Inc. (NASDAQ:OCUL) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect Ocular Therapeutix to post earnings of ($0.54) per share for the quarter.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.05). The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.46) earnings per share. On average, analysts expect Ocular Therapeutix to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ocular Therapeutix, Inc. (NASDAQ OCUL) opened at $5.73 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.20 and a current ratio of 5.20. Ocular Therapeutix, Inc. has a 52-week low of $4.90 and a 52-week high of $11.91.

A hedge fund recently raised its stake in Ocular Therapeutix stock. The Manufacturers Life Insurance Company grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 24.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,739 shares of the biopharmaceutical company’s stock after purchasing an additional 3,650 shares during the period. The Manufacturers Life Insurance Company owned about 0.06% of Ocular Therapeutix worth $174,000 as of its most recent filing with the Securities & Exchange Commission. 53.25% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently commented on OCUL. Zacks Investment Research downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Guggenheim began coverage on Ocular Therapeutix in a research report on Monday, October 23rd. They set a “buy” rating and a $12.00 target price for the company. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research report on Monday, September 25th. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 21st. Finally, BTIG Research reiterated a “neutral” rating on shares of Ocular Therapeutix in a research report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $22.29.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/ocular-therapeutix-inc-ocul-scheduled-to-post-earnings-on-tuesday/1679883.html.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.